Method for Reducing the Likelihood of Developing Cancer in an Individual Human Being

Abstract

A person's intestinal (gut), oral or skin microbiota is modified using specific combinations of pre-biotics, pro-biotics and / or anti-biotics to establish a defined microbiota that can treat and / or reduce the likelihood that individuals will experience various diseases, including cancer. The employment of various bacteria, whether in particular combinations or after being modified using CRISPR-type systems, leads to improved outcomes when checkpoint inhibitors are used to treat various forms of cancer. One embodiment is directed to a method for reducing the likelihood of developing cancer by providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species. The level of Roseburia and Faecalibacterium prausnitzii, and / or Akkermansia muciniphila bacteria are increased in the individual's gut microbiome such that when an individual is administered an immune checkpoint inhibitor, its function is enhanced due to the presence of the bacterial population.

Description

RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 16 / 782,364, filed Feb. 5, 2020, which is a continuation-in-part of U.S. patent application Ser. No. 16 / 423,375, filed May 28, 2018 (now U.S. Pat. No. 10,555,976, issued Feb. 11, 2020), which is a continuation of U.S. patent application Ser. No. 16 / 160,336, filed Oct. 15, 2018 (now U.S. Pat. No. 10,314,866, issued Jun. 11, 2019), which is a continuation of U.S. patent application Ser. No. 15 / 403,823, filed Jan. 11, 2017 (now U.S. Pat. No. 10,111,913, issued Oct. 30, 2018), which is a non-provisional of U.S. Provisional Patent Application Ser. No. 62 / 296,186, filed on Feb. 17, 2016.[0002]This application also is a continuation-in-part application of U.S. patent application Ser. No. 15 / 270,034, filed Sep. 20, 2016 (now U.S. Pat. No. 9,750,802, issued Sep. 5, 2017), which is a continuation-in-part application of U.S. patent application Ser. No. 14 / 954,074, filed on Nov. 30, 2015 (now...

AI Technical Summary

Benefits of technology

The present invention is about modifying a person's microbiota (gut, oral, or skin) using specific combinations of pre-biotics, pro-biotics, and / or anti-biotics to treat and reduce the likelihood of various diseases, including cancer. Specifically, the invention provides a method for averting or reducing cancer by employing bacteria modified to address p53 deficiency and using these modified bacteria to pre-treat a person prior to cancer treatment, lessen the detrimental effects of treatment, and restore the person's microbiomes after treatment. The use of modified skin bacteria to treat melanoma is also one aspect of the invention, which provides a way to treat skin cancer by reducing the spread and health of cancer cells while promoting beneficial bacteria.

Problems solved by technology

Moreover, lengthening life spans correlate with increased time in hospitals or long-term care facilities and exposure to drug-resistant pathogens.

One theory is that as a person ages, their immune system changes and is less robust in addressing bacterial infections.

As obesity and insulin resistance reach epidemic proportions in industrialized countries, the prevalence of both NAFLD and NASH is increasing and is therefore considered to be a major health hazard.

Consequently, therapeutic options are poor.

Cachexia is a positive risk factor for death, meaning that if a patient has cachexia, the chance of death from the underlying condition is increased dramatically.

Only limited treatment options exist for patients with clinical cancer cachexia.

Further studies have suggested that the microbiota and their associated metabolites are not only closely related to carcinogenesis by inducing inflammation and immune dysregulation, which lead to genetic instability, but also interfere with the pharmacodynamics of anticancer agents.

NAFLD is considered to be a major risk factor for HCC.

Improving the outcomes of such treatments by an understanding of how a person's microbiome can be beneficially manipulated to advance positive outcomes that employ checkpoint inhibitors is a long sought but unsolved issue.

Images